ideasIdea
Guaranteed-quality childhood cancer medicines free of charge in 50 countries
Most children with cancer in rich countries are cured; most in poor countries are not, often because cheap drugs are missing. A global platform now ships quality drugs free; scaling it to 50 countries would be one of the highest-value cancer interventions available.
The WHO and St. Jude Global Platform for Access to Childhood Cancer Medicines began deliveries in 2025 to a first set of countries, providing an uninterrupted supply of quality-assured medicines at no cost. Childhood cancers are highly curable with generic drugs, so the return per dollar is very high. The proposal is to commit the funding and logistics to reach 50 countries and to measure survival, not deliveries, as the outcome.
Hypothesis
Countries receiving platform medicines will show a measurable rise in two-year survival for acute lymphoblastic leukaemia and Hodgkin lymphoma within four years of first delivery, compared with pre-platform baselines from hospital registries.
Rationale
The drugs are cheap, off-patent, and the protocols are standard; the gap is supply reliability and quality assurance, both of which a platform can fix at scale.
What would test it
Prospective survival tracking in platform hospitals using the SIOP-style hospital-based registries, with abandonment and toxic-death rates as secondary endpoints.
Maturity
being tested at scale
Who has to act
philanthropy
Cost to try
Large (over $50M)
Years to first evidence
5
Bottlenecks it attacks
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.